Contribution of Sustained Ca2+ Elevation for Nitric Oxide Production in Endothelial Cells and Subsequent Modulation of Ca2+ Transient in Vascular Smooth Muscle Cells in Coculture
Overview
Authors
Affiliations
To elucidate the intracellular Ca2+ (Ca2+i ) transient responsible for nitric oxide (NO) production in endothelial cells (ECs) and the subsequent Ca2+i reduction in vascular smooth muscle cells (VSMCs), we administrated four agonists with different Ca2+i-mobilizing mechanisms for both cells in iso- or coculture. We monitored the Ca2+i of both cells by two-dimensional fura-2 imaging, simultaneously measuring NO production as NO2-. The order of potency of the agonists in terms of the peak Ca2+i in ECs was bradykinin (100 nM) > ATP (10 microM) > ionomycin (50 nM) > thapsigargin (1 microM). In contrast, the order in reference to both the extent of Ca2+i reduction in cocultured VSMCs and the elevation in NO production over the level of basal release in ECs completely matched and was ranked as thapsigargin > ionomycin > ATP > bradykinin. Treatment by NG-monomethyl-L-arginine monoacetate but not indomethacin or glybenclamide restored the Ca2+i response in cocultured VSMCs to the isoculture level. In ECs, when the Ca2+ influx was blocked by Ni2+ or by chelating extracellular Ca2+, all four agonists markedly decreased NO production, the half decay time of the Ca2+i degenerating phase, and the area under the Ca2+i curve. The amount of produced NO hyperbolically correlated to the half decay time and the area under the Ca2+i curve but not to the Ca2+i peak level. Thus, the sustained elevation of Ca2+i in ECs, mainly a result of Ca2+ influx, determines the active NO production and subsequent Ca2+i reduction in adjacent VSMCs. Furthermore, L-arginine but not D-arginine or L-lysine at high dose (5 mM) without agonist enhanced the NO production, weakly reduced the Ca2+i in ECs, and markedly decreased the Ca2+i in VSMCs, demonstrating the autocrine and paracrine effects of NO (Shin, W. S., Sasaki, T., Kato, M., Hara, K., Seko, A., Yang, W. D., Shimamoto, N., Sugimoto, T., and Toyo-oka, T. (1992) J. Biol. Chem. 267, 20377-20382).
Smeir M, Chumala P, Katselis G, Liu L Biomolecules. 2024; 14(1).
PMID: 38254711 PMC: 10813790. DOI: 10.3390/biom14010111.
Pereira da Silva J, Ballejo G Einstein (Sao Paulo). 2019; 17(3):eAO4600.
PMID: 31166411 PMC: 6550436. DOI: 10.31744/einstein_journal/2019AO4600.
Qu Y, Wang L, Zhong H, Liu Y, Tang N, Zhu L Mol Med Rep. 2017; 16(4):4613-4619.
PMID: 28791397 PMC: 5647016. DOI: 10.3892/mmr.2017.7164.
Chen J, Wang H, Xu W, Wei S, Li H, Mei Y Oncotarget. 2016; 7(35):56129-56146.
PMID: 27276708 PMC: 5302901. DOI: 10.18632/oncotarget.9794.
Andrews A, Jaron D, Buerk D, Barbee K Cell Mol Bioeng. 2014; 7(4):510-520.
PMID: 25386222 PMC: 4224574. DOI: 10.1007/s12195-014-0351-x.